ATNM
Price
$1.48
Change
-$0.05 (-3.27%)
Updated
Oct 30 closing price
Capitalization
46.53M
12 days until earnings call
Intraday BUY SELL Signals
QNRX
Price
$4.57
Change
+$0.41 (+9.86%)
Updated
Oct 30 closing price
Capitalization
9.18M
4 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATNM vs QNRX

ATNM vs QNRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ATNM vs. QNRX commentary
Nov 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATNM is a Buy and QNRX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ATNM with price predictions
Oct 30, 2026

Momentum Indicator for ATNM turns positive, indicating new upward trend

ATNM saw its Momentum Indicator move above the 0 level on October 19, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 71 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ATNM just turned positive on October 19, 2026. Looking at past instances where ATNM's MACD turned positive, the stock continued to rise in 38 of 50 cases over the following month. The odds of a continued upward trend are 76%.

ATNM moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ATNM crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

The 50-day moving average for ATNM moved above the 200-day moving average on October 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +23.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in 165 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

Bearish Trend Analysis

The 10-day RSI Indicator for ATNM moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 20 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 45 cases where ATNM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

ATNM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ATNM entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ATNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.536) is normal, around the industry mean (3.162). P/E Ratio (4.229) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (1.105) is also within normal values, averaging (439.647).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for QNRX with price predictions
Oct 30, 2026

QNRX's Stochastic Oscillator reaching overbought zone

The Stochastic Oscillator for QNRX moved into overbought territory on October 30, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

QNRX moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for QNRX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

QNRX broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for QNRX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where QNRX's RSI Oscillator exited the oversold zone, 40 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on QNRX as a result. In 63 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for QNRX just turned positive on October 23, 2026. Looking at past instances where QNRX's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.

Following a +3.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where QNRX advanced for three days, in 176 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. QNRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.334) is normal, around the industry mean (3.162). P/E Ratio (-0.806) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ATNM vs QNRX: Fundamental Ratings
ATNM
QNRX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
22100
PRICE GROWTH RATING
1..100
3562
P/E GROWTH RATING
1..100
7100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QNRX's Valuation (64) in the Biotechnology industry is in the same range as ATNM (74). This means that QNRX’s stock grew similarly to ATNM’s over the last 12 months.

QNRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATNM (100). This means that QNRX’s stock grew similarly to ATNM’s over the last 12 months.

ATNM's SMR Rating (22) in the Biotechnology industry is significantly better than the same rating for QNRX (100). This means that ATNM’s stock grew significantly faster than QNRX’s over the last 12 months.

ATNM's Price Growth Rating (35) in the Biotechnology industry is in the same range as QNRX (62). This means that ATNM’s stock grew similarly to QNRX’s over the last 12 months.

ATNM's P/E Growth Rating (7) in the Biotechnology industry is significantly better than the same rating for QNRX (100). This means that ATNM’s stock grew significantly faster than QNRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATNMQNRX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 13 days ago
72%
Bullish Trend 13 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
COMPARISON
Comparison
Nov 02, 2026
Stock price -- (ATNM: $1.48 vs. QNRX: $4.57)
Brand notoriety: ATNM and QNRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATNM: 86% vs. QNRX: 5%
Market capitalization -- ATNM: $46.53M vs. QNRX: $9.18M
ATNM [@Biotechnology] is valued at $46.53M. QNRX’s [@Biotechnology] market capitalization is $9.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $141.65B. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATNM’s FA Score shows that 2 FA rating(s) are green while QNRX’s FA Score has 0 green FA rating(s).

  • ATNM’s FA Score: 2 green, 3 red.
  • QNRX’s FA Score: 0 green, 5 red.
According to our system of comparison, ATNM is a better buy in the long-term than QNRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATNM’s TA Score shows that 6 TA indicator(s) are bullish while QNRX’s TA Score has 4 bullish TA indicator(s).

  • ATNM’s TA Score: 6 bullish, 5 bearish.
  • QNRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ATNM is a better buy in the short-term than QNRX.

Price Growth

ATNM (@Biotechnology) experienced а -2.63% price change this week, while QNRX (@Biotechnology) price change was +12.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.

Reported Earning Dates

ATNM is expected to report earnings on Nov 13, 2026.

QNRX is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (+0.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ATNM
Daily Signal:
Gain/Loss:
QNRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ATNM and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATNM has been loosely correlated with PDSB. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ATNM jumps, then PDSB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATNM
1D Price
Change %
ATNM100%
-3.27%
PDSB - ATNM
35%
Loosely correlated
-7.10%
WVE - ATNM
34%
Loosely correlated
-1.10%
CRBU - ATNM
33%
Loosely correlated
-4.90%
MGX - ATNM
33%
Poorly correlated
-6.01%
AMLX - ATNM
32%
Poorly correlated
+0.63%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GUT5.310.04
+0.76%
Gabelli Utility Trust
GIGB44.330.12
+0.26%
Goldman Sachs Access Investment Grade Corporate Bond ETF (GIGB)
QCRH101.38-0.93
-0.91%
QCR Holdings
SHIP15.91-0.19
-1.18%
Seanergy Maritime Holdings Corp
CATO2.31-0.07
-2.94%
CATO Corp